Patient Care Settings
Cancer, Hospital Medicine
Dr. Eric Huselton received his medical degree from SUNY Downstate College of Medicine in 2012. He completed an Internal Medicine Residency Training Program and a Hematology/Oncology Fellowship at Washington University in Saint Louis/Bames Jewish Hospital in 2015 and 2018, respectively. Dr. Huselton is certified by the American Board of Internal Medicine.
Dr. Huselton is an Assistant Professor in the Division of Hematology and Oncology at the University of Rochester School of Medicine and Dentistry.
Dr. Huselton's special interests include allogenic hematopoietic cell transplant, haploidentical hematopoietic cell transplant, AML, MDS and hematologic malignancies. He aims to provide the best care by incorporating new treatments based on the most recent data, including clinical trials, targeted therapies, immunotherapy and cellular therapies. Dr. Huselton's hobbies include sailing, hiking and cooking.
MD | SUNY Downstate Medical Center College of Nursing
Post-doctoral Training & Residency
07/01/2015 - 06/30/2018
Fellowship in Hematology & Oncology at Washington University Dept of Ophthalmology-GME
07/01/2013 - 06/30/2015
Residency in Internal Medicine at Washington University in St. Louis
06/01/2012 - 06/30/2013
Internship in Internal Medicine at Washington University in St. Louis
VIEW ALL expand_more
2019 - 2022
Wilmot Fellowship Award
Sponsor: Wilmot Cancer Institute
Location: Rochester, NY
Travel Award, Society of Hematologic Oncology
Harold A. Lyons Award for Excellence in Clinical Medicine
Alpha Omega Alpha
Location: SUNY Downstate College of Medicine
Downstate Alumni Summer Research Fellow
VIEW ALL expand_more
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Lead Researcher: Eric J Huselton
The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is expected based on historical controls. The investigators will also prospectively determine the relapse-free and overall survival of patients who have not cleared their mutations. Because the relapse rate of patients with persistent mutations is expected to be high, treatment with either standard of care consolidation therapy alone or alloSCT will be permitted, at the discretion of the treating physician.
View Study Details
Loh KP, Sanapala C, Jensen-Battaglia M, Rana A, Sohn MB, Watson E, Gilmore N, Klepin HD, Mendler JH, Liesveld J, Huselton E, LoCastro M, Susiarjo M, Netherby-Winslow C, Williams AM, Mustian K, Vertino P, Janelsins MC. "Exercise and epigenetic ages in older adults with myeloid malignancies." European journal of medical research.. 2023 May 30; 28(1):180. Epub 2023 May 30.
LoCastro M, Wang Y, Sanapala C, Jensen-Battaglia M, Wittink M, Norton S, Klepin HD, Richardson DR, Mendler JH, Liesveld J, Huselton E, Loh KP. "Patient preferences, regret, and health-related quality of life among older adults with acute myeloid leukemia: A pilot longitudinal study." Journal of geriatric oncology.. 2023 May 25; 14(5):101529. Epub 2023 May 25.
Rashidi A, Huselton EJ, Stefanski HE, DeFor TE, Shanley R, Choi J, DiPersio JF, Juckett M, Miller JS, Weisdorf DJ, Schroeder MA. "A multicenter phase 2 clinical trial of 10-day decitabine, dose-escalated donor lymphocyte infusion, and ruxolitinib for relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic cell transplantation." Transplantation and cellular therapy.. 2023 Feb 17; Epub 2023 Feb 17.
VIEW ALL PUBLICATIONS